Radiopharmaceuticals in Nuclear Medicine - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509246061

Publication Date:

September 10, 2024

Pages:

166

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The global market for Radiopharmaceuticals in Nuclear Medicine was estimated to be worth US$ 4804.6 million in 2023 and is forecast to a readjusted size of US$ 6988.2 million by 2030 with a CAGR of 5.0% during the forecast period 2024-2030
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceuticals in Nuclear Medicine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Radiopharmaceuticals in Nuclear Medicine by region & country, by Type, and by Application.
The Radiopharmaceuticals in Nuclear Medicine market size, estimations, and forecasts are provided in terms of sales volume (K MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceuticals in Nuclear Medicine.
麻豆原创 Segmentation
By Company
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Segment by Type:
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Segment by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Radiopharmaceuticals in Nuclear Medicine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Radiopharmaceuticals in Nuclear Medicine Product Introduction
1.2 Global Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Size Forecast
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value (2019-2030)
1.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume (2019-2030)
1.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Price (2019-2030)
1.3 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Trends & Drivers
1.3.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
1.3.2 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Drivers & Opportunity
1.3.3 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Challenges
1.3.4 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Radiopharmaceuticals in Nuclear Medicine Players Revenue Ranking (2023)
2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Company (2019-2024)
2.3 Global Radiopharmaceuticals in Nuclear Medicine Players Sales Volume Ranking (2023)
2.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Company Players (2019-2024)
2.5 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Company (2019-2024)
2.6 Key Manufacturers Radiopharmaceuticals in Nuclear Medicine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Radiopharmaceuticals in Nuclear Medicine
2.9 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Competitive Analysis
2.9.1 Radiopharmaceuticals in Nuclear Medicine 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Radiopharmaceuticals in Nuclear Medicine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceuticals in Nuclear Medicine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Diagnostic Radiopharmaceuticals
3.1.2 Therapy Radiopharmaceuticals
3.1.3 Enriched Stable Isotopes
3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value, by Type (2019-2030)
3.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value, by Type (%) (2019-2030)
3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type
3.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, by Type (2019-2030)
3.3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, by Type (%) (2019-2030)
3.4 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Diagnostic Application
4.1.2 Therapeutic Application
4.1.3 Research
4.1.4 Pharmaceutical
4.1.5 Other
4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value, by Application (2019-2030)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value, by Application (%) (2019-2030)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application
4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, by Application (2019-2030)
4.3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume, by Application (%) (2019-2030)
4.4 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region
5.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (2019-2024)
5.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (2025-2030)
5.1.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Value by Region (%), (2019-2030)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Region
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Region (2019-2024)
5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Region (2025-2030)
5.2.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume by Region (%), (2019-2030)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
5.4.2 North America Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
5.5.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
5.6.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
5.7.2 South America Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
5.8.2 Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Radiopharmaceuticals in Nuclear Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Radiopharmaceuticals in Nuclear Medicine Sales Value
6.2.1 Key Countries/Regions Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Radiopharmaceuticals in Nuclear Medicine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
6.3.2 United States Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Radiopharmaceuticals in Nuclear Medicine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
6.4.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Radiopharmaceuticals in Nuclear Medicine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
6.5.2 China Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Radiopharmaceuticals in Nuclear Medicine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
6.6.2 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Radiopharmaceuticals in Nuclear Medicine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
6.7.2 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Radiopharmaceuticals in Nuclear Medicine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
6.8.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Radiopharmaceuticals in Nuclear Medicine Sales Value, 2019-2030
6.9.2 India Radiopharmaceuticals in Nuclear Medicine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Radiopharmaceuticals in Nuclear Medicine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bracco Imaging S.P.A.
7.1.1 Bracco Imaging S.P.A. Company Information
7.1.2 Bracco Imaging S.P.A. Introduction and Business Overview
7.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.1.5 Bracco Imaging S.P.A. Recent Development
7.2 Cambridge Isotope Laboratories, Inc.
7.2.1 Cambridge Isotope Laboratories, Inc. Company Information
7.2.2 Cambridge Isotope Laboratories, Inc. Introduction and Business Overview
7.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.2.5 Cambridge Isotope Laboratories, Inc. Recent Development
7.3 Cardinal Health, Inc.
7.3.1 Cardinal Health, Inc. Company Information
7.3.2 Cardinal Health, Inc. Introduction and Business Overview
7.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.3.5 Cardinal Health, Inc. Recent Development
7.4 Covidien, Plc
7.4.1 Covidien, Plc Company Information
7.4.2 Covidien, Plc Introduction and Business Overview
7.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.4.5 Covidien, Plc Recent Development
7.5 Eczacibasi-Monrol
7.5.1 Eczacibasi-Monrol Company Information
7.5.2 Eczacibasi-Monrol Introduction and Business Overview
7.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.5.5 Eczacibasi-Monrol Recent Development
7.6 Fujifilm Holdings Corporation
7.6.1 Fujifilm Holdings Corporation Company Information
7.6.2 Fujifilm Holdings Corporation Introduction and Business Overview
7.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.6.5 Fujifilm Holdings Corporation Recent Development
7.7 GE Healthcare (Subsidiary Of General Electric Company)
7.7.1 GE Healthcare (Subsidiary Of General Electric Company) Company Information
7.7.2 GE Healthcare (Subsidiary Of General Electric Company) Introduction and Business Overview
7.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Development
7.8 IBA Group
7.8.1 IBA Group Company Information
7.8.2 IBA Group Introduction and Business Overview
7.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.8.5 IBA Group Recent Development
7.9 Isotec, Inc. (Sigma-Aldrich)
7.9.1 Isotec, Inc. (Sigma-Aldrich) Company Information
7.9.2 Isotec, Inc. (Sigma-Aldrich) Introduction and Business Overview
7.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Development
7.10 Lantheus Medical Imaging, Inc.
7.10.1 Lantheus Medical Imaging, Inc. Company Information
7.10.2 Lantheus Medical Imaging, Inc. Introduction and Business Overview
7.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.10.5 Lantheus Medical Imaging, Inc. Recent Development
7.11 Nordion, Inc.
7.11.1 Nordion, Inc. Company Information
7.11.2 Nordion, Inc. Introduction and Business Overview
7.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.11.5 Nordion, Inc. Recent Development
7.12 Ntp Radioisotopes (Pty), Ltd.
7.12.1 Ntp Radioisotopes (Pty), Ltd. Company Information
7.12.2 Ntp Radioisotopes (Pty), Ltd. Introduction and Business Overview
7.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Development
7.13 Siemens Healthcare (Subsidiary Of Siemens AG)
7.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Company Information
7.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Introduction and Business Overview
7.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Development
7.14 Taiyo Nippon Sanso Corporation
7.14.1 Taiyo Nippon Sanso Corporation Company Information
7.14.2 Taiyo Nippon Sanso Corporation Introduction and Business Overview
7.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.14.5 Taiyo Nippon Sanso Corporation Recent Development
7.15 Urenco Limited
7.15.1 Urenco Limited Company Information
7.15.2 Urenco Limited Introduction and Business Overview
7.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.15.5 Urenco Limited Recent Development
7.16 Rotem Industries, Ltd., Inc.
7.16.1 Rotem Industries, Ltd., Inc. Company Information
7.16.2 Rotem Industries, Ltd., Inc. Introduction and Business Overview
7.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.16.5 Rotem Industries, Ltd., Inc. Recent Development
7.17 Australian Nuclear Association And Technology Organization (ANSTO)
7.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Company Information
7.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Introduction and Business Overview
7.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Development
7.18 Board of Radiation And Isotope Technology (BRIT)
7.18.1 Board of Radiation And Isotope Technology (BRIT) Company Information
7.18.2 Board of Radiation And Isotope Technology (BRIT) Introduction and Business Overview
7.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Development
7.19 Institute of Atomic Energy Polatom Radioisotope Centre
7.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Company Information
7.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Introduction and Business Overview
7.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Development
7.20 Institute of Isotopes Co., Ltd.
7.20.1 Institute of Isotopes Co., Ltd. Company Information
7.20.2 Institute of Isotopes Co., Ltd. Introduction and Business Overview
7.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.20.5 Institute of Isotopes Co., Ltd. Recent Development
7.21 Institute Of Radioelement (IRE)
7.21.1 Institute Of Radioelement (IRE) Company Information
7.21.2 Institute Of Radioelement (IRE) Introduction and Business Overview
7.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
7.21.4 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Offerings
7.21.5 Institute Of Radioelement (IRE) Recent Development
8 Industry Chain Analysis
8.1 Radiopharmaceuticals in Nuclear Medicine Industrial Chain
8.2 Radiopharmaceuticals in Nuclear Medicine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Radiopharmaceuticals in Nuclear Medicine Sales Model
8.5.2 Sales Channel
8.5.3 Radiopharmaceuticals in Nuclear Medicine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.